Lisata and Kuva extend exclusive negotiation deadline to March 7, 2026 for acquisition

LISATA THERAPEUTICS, INC.

Amendment to binding term sheet extends expiration from Feb 28 to March 7, 2026.
Kuva Labs to acquire Lisata via tender offer and short-form merger under Section 251(h).
No other changes to term sheet; parties continue negotiating purchase agreement.
Acquisition remains subject to tender offer conditions and regulatory approvals.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LISATA THERAPEUTICS, INC. amended Term Sheet Amendment with Kuva Labs Inc. (effective 2026-02-27).

Action: amendment
Agreement: merger
Counterparty: Kuva Labs Inc.
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, Lisata and Kuva entered into an amendment to the Term Sheet (the “Term Sheet Amendment”), whereby the parties agreed to extend the expiration date of the Term Sheet to March 7, 2026.

View on SEC.gov

Browse all material agreements →

LISATA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000320017-26-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.